Treating opioid use under California's Proposition 36: Differential outcomes by treatment modality

Journal of Psychoactive Drugs

Volumn 43, Issue 1 SUPPLIMENT, 2011, Pages 77-83

  Conner, Bradley T ^a   Hamptonb, Ashley S ^a   Hunter, Jeremy ^b   Urada, Darren ^c  

^a TEMPLE UNIVERSITY   (United States)

^b SimulStat Incorporated   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Buprenorphine; Criminal justice; Methadone; Narcotic replacement therapy; Opioids

Indexed keywords

METHADONE; NARCOTIC AGENT; OPIATE;

ARTICLE; DRUG EFFICACY; HOME CARE; HOSPITAL DISCHARGE; HUMAN; LAW ENFORCEMENT; MAJOR CLINICAL STUDY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OUTPATIENT; PATIENT REFERRAL; TREATMENT OUTCOME; TREATMENT PLANNING; CRIMINAL LAW; UNITED STATES;

CALIFORNIA; CRIMINAL LAW; HUMANS; OPIOID-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84855550737     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2011.602281     Document Type: Article

References (18)

1. Banta-Green, C.J.; Maynard, C.; Koepsell, T.D.; Wells, E.A. & Donovan, D.M. 2009. Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users. Addiction 104: 775-83.
2. Cartwright, W.S. 2008. Economic costs of drug abuse: Financial, cost of illness, and services. Journal of Substance Abuse Treatment 34: 224-33.
3. Conner, B.T. 2008. Narcotic treatment programs. In: Evaluation of Proposition 36: The Substance Abuse and Crime Prevention Act of 2000 2008 Report. Los Angeles: University of California, Los Angeles.
4. French, M.T.; Popovici, I. & Tapsell, L. 2008. The economic costs of substance abuse treatment: Updated estimates and cost bands for program assessment and reimbursement. Journal of Substance Abuse Treatment 35: 462-69.
5. Hser, Y.-I.; Anglin, M.D. & Fletcher, B. 1998. Comparative treatment effectiveness: Effects of program modality and client drug dependence history on drug use reduction. Journal of Substance Abuse Treatment 15: 513-23.
6. Joseph, H.; Stancliff, S. & Langrod, J. 2000. Methadone maintenance treatment: A review of the historical and clinical issues. Mount Sinai Journal of Medicine 67: 347-64.
7. Ling, W.; Charuvastra, C.; Collins, J.F.; Batki, S.; Brown, L.S. Jr.; Kintaudi, P.; Wesson, D.R.; McNicholas, L.; Tusel, D.J.; Malkerneker, U.; Renner, J.A. Jr.; Santos, E.; Casadonte, P.; Fye, C.; Stine, S.; Wang, R.I. & Segal, D. 1998. Buprenorphine maintenance treatment of opioid dependence: A multicenter, randomized clinical trial. Addiction 93: 475-86.
8. Mattick, R. P.; Breen, C.; Kimber, J. & Davoli, M. 2009. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews Issue 3: 1-34.
9. National Institute on Drug Abuse (NIDA). 1999. Principles of Drug Addiction Treatment. NIH Publication No. 99-4180. Washington DC: National Institutes of Health.
10. National Institutes of Health Consensus Development Program. 1997. Effective Medical Treatment of Opioid Addiction. Available at http://consensus.nih.gov/1997/1998TreatOpioidAddiction108html.htm.
11. Strain, E.C.; Stoller, K.; Walsh, S.L. & Bigelow G.E. 2000. Effects of buprenorphine versus buprenorphine/naloxone tablets in nondependent opioid abusers. Psychopharmacology (Berlin) 148: 374-83.
12. Substance Abuse and Mental Health Services Administration (SAMHSA). 2010. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4856 Findings.
13. Rockville, MD: SAMHSA. Substance Abuse and Mental Health Services Administration (SAMHSA). 2009. Treatment Episode Data Set (TEDS). Highlights-2007. National Admissions to Substance Abuse Treatment Services. Office of Applied Studies, DASIS Series: S-45, DHHS Publication No. SMA 09-4360.
14. Rockville, MD: SAMHSA. United States Food and Drug Administration (US FDA). 2002. Subutex and Suboxone Approved to Treat Opioid Dependence. Talk Paper T02-38, October 8, 2002. Silver Spring, MD: USFDA. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/ucm191521.htm.
15. UCLA Integrated Substance Abuse Programs (ISAP). 2011. SACPA Reports. (Website). Los Angeles: UCLA ISAP. Accessed at: http://www.uclaisap.org/Prop36/html/reports.html.
16. Urada, D.; Hawken, A.; Conner, B.T.; Evans, E.; Anglin, M.D.; Yang, J.; Teruya, C.; Herbeck, D.; Fan, J.; Rutkowski, B.; Gonzales, R.; Rawson, R.; Grella, C.; Prendergast, M.; Hser, Y.; Hunter, J. & Poe, A. 2008. Evaluation of Proposition 36: The Substance Abuse and Crime Prevention Act of 2000: 2008 Report. Available at http:// www.uclaisap.org/Prop36/documents/2008%20Final%20 Report.pdf.
17. Veilleux, J.C.; Colvin, P.J.; Anderson, J.; York, C. & Heinz, A.J. 2010. A review of opioid dependence treatment: Pharmacological and psychosocial interventions to treat opioid addiction. Clinical Psychology Review 30: 155-66.
18. Walsh, S.L.; Nuzzo, P.A.; Lofwall, M.R. & Holtman, Jr., J.R. 2008. The relative abuse liability of oral ozycodone, hydrocodone, and hydromorphone assessed in prescription opioid abusers. Drug and Alcohol Dependence 98: 191-202.